腺病毒载体口蹄疫亚单位疫苗在荷斯坦阉牛中的保护持续时间与体液免疫
三项研究评估商业AdtFMD疫苗单次接种后6或9个月经舌皮内攻毒的保护比例,并比较经皮、肌内、皮下接种途径对临床结局和体液免疫的影响。结果显示6个月保护率分别为经皮100%、肌内80%、皮下60%,9个月降至经皮33%、肌内20%;接种后14天普遍出现中和抗体,抗体分泌细胞28天后消失。
要点
- 单剂Adt.A24疫苗6个月保护率经皮100%、肌内80%、皮下60%,9个月降至33%和20%。
- 接种后14天血清普遍含FMDV特异性中和抗体,抗体分泌细胞28天后检测不到。
- 抗体介导免疫随时间衰减可能与FMDV特异性抗体半衰期有关。
核心结论
- 商业AdtFMD疫苗单次接种在牛中6个月时诱导临床保护,但9个月时保护率下降。
- 经皮接种途径在6个月时保护比例高于肌内和皮下途径。
- 抗FMDV抗体分泌细胞在接种后28天已检测不到,体液免疫随时间衰减。
研究设计与样本
- 三项研究评估商业AdtFMD疫苗(表达FMDV A24 Cruzeiro株衣壳蛋白)单次接种后6或9个月经舌皮内活病毒攻毒的保护比例。
- 研究比较经皮、肌内、皮下三种接种途径对临床结局和体液免疫的影响。
- 研究对象为荷斯坦阉牛,疫苗已在美国获得牛临时许可。
主要发现
- 6个月攻毒保护率:经皮100%、肌内80%、皮下60%。
- 9个月攻毒保护率:经皮33%、肌内20%。
- 接种后14天免疫牛血清普遍含FMDV特异性中和抗体。
- 接种后早期外周血可检测抗FMDV抗体分泌细胞,28天后消失。
临床怎么用
- 该疫苗单次接种可提供6个月临床保护,9个月时保护率下降,需考虑加强免疫时机。
- 经皮接种在6个月时保护比例最高,可作为优先考虑的接种途径。
- 接种后14天可检测中和抗体作为体液免疫应答指标。
局限性
- 原文未报告研究样本量、置信区间和P值。
- 保护数据基于舌皮内攻毒模型,外推田间自然感染需谨慎。
- 原文未报告9个月皮下接种途径的保护数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Foot-and-mouth disease (FMD) is a highly contagious viral infection of cloven hooved animals that continues to cause economic disruption in both endemic countries or when introduced into a formally FMD free country. Vaccines that protect against clinical disease and virus shedding are critical to control FMD. The replication deficient human adenovirus serotype 5 (Ad5) vaccine vector expressing empty FMD virus (FMDV) capsid, AdtFMD, is a promising new vaccine platform. With no shedding or spreading of viral vector detected in field trials, this vaccine is very safe to manufacture, as there is no requirement for high containment faciitites. Here, we describe three studies assessing the proportion of animals protected from clinical vesicular disease (foot lesions) following live-FMDV challenge by intradermolingual inoculation at 6 or 9 months following a single vaccination with the commercial AdtFMD vaccine, provisionally licensed for cattle in the United States. Further, we tested the effect of vaccination route (transdermal, intramuscular, subcutaneous) on clinical outcome and humoral immunity. Results demonstrate that a single dose vaccination in cattle with the commercial vaccine vector expressing capsid proteins of the FMDV strain A24 Cruzeiro (Adt.A24), induced protection against clinical FMD at 6 months (100% transdermal, 80% intramuscular, and 60% subcutaneous) that waned by 9 months post-vaccination (33% transdermal and 20% intramuscular). Post-vaccination serum from immunized cattle (all studies) generally contained FMDV specific neutralizing antibodies by day 14. Anti-FMDV antibody secreting cells are detected in peripheral blood early following vaccination, but are absent after 28 days post-vaccination. Thus, the decay in antibody mediated immunity over time is likely a function of FMDV-specific antibody half-life. These data reveal the short time span of anti-FMDV antibody secreting cells (ASCs) and important performance characteristics of needle-free vaccination with a recombinant vectored subunit vaccine for FMDV.
引用
- Sitt T, Kenney M, Barrera J, et al. Duration of protection and humoral immunity induced by an adenovirus-vectored subunit vaccine for foot-and-mouth disease (FMD) in Holstein steers. Vaccine. 2019. PMID: 31493951. doi:10.1016/j.vaccine.2019.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。